scholarly journals Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives

Microbiology ◽  
2010 ◽  
Vol 156 (11) ◽  
pp. 3205-3215 ◽  
Author(s):  
Anne Salonen ◽  
Willem M. de Vos ◽  
Airi Palva

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that has been associated with aberrant microbiota. This review focuses on the recent molecular insights generated by analysing the intestinal microbiota in subjects suffering from IBS. Special emphasis is given to studies that compare and contrast the microbiota of healthy subjects with that of IBS patients classified into different subgroups based on their predominant bowel pattern as defined by the Rome criteria. The current data available from a limited number of patients do not reveal pronounced and reproducible IBS-related deviations of entire phylogenetic or functional microbial groups, but rather support the concept that IBS patients have alterations in the proportions of commensals with interrelated changes in the metabolic output and overall microbial ecology. The lack of apparent similarities in the taxonomy of microbiota in IBS patients may partially arise from the fact that the applied molecular methods, the nature and location of IBS subjects, and the statistical power of the studies have varied considerably. Most recent advances, especially the finding that several uncharacterized phylotypes show non-random segregation between healthy and IBS subjects, indicate the possibility of discovering bacteria specific for IBS. Moreover, tools are being developed for the functional analysis of the relationship between the intestinal microbiota and IBS. These approaches may be instrumental in the evaluation of the ecological dysbiosis hypothesis in the gut ecosystem. Finally, we discuss the future outlook for research avenues and candidate microbial biomarkers that may eventually be used in IBS diagnosis.

Nutrients ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1506
Author(s):  
Annamaria Altomare ◽  
Claudia Di Rosa ◽  
Elena Imperia ◽  
Sara Emerenziani ◽  
Michele Cicala ◽  
...  

Irritable Bowel Syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by abdominal pain associated with defecation or a change in bowel habits. Gut microbiota, which acts as a real organ with well-defined functions, is in a mutualistic relationship with the host, harvesting additional energy and nutrients from the diet and protecting the host from pathogens; specific alterations in its composition seem to play a crucial role in IBS pathophysiology. It is well known that diet can significantly modulate the intestinal microbiota profile but it is less known how different nutritional approach effective in IBS patients, such as the low-FODMAP diet, could be responsible of intestinal microbiota changes, thus influencing the presence of gastrointestinal (GI) symptoms. The aim of this review was to explore the effects of different nutritional protocols (e.g., traditional nutritional advice, low-FODMAP diet, gluten-free diet, etc.) on IBS-D symptoms and on intestinal microbiota variations in both IBS-D patients and healthy subjects. To date, an ideal nutritional protocol does not exist for IBS-D patients but it seems crucial to consider the effect of the different nutritional approaches on the intestinal microbiota composition to better define an efficient strategy to manage this functional disorder.


2013 ◽  
Vol 305 (8) ◽  
pp. G529-G541 ◽  
Author(s):  
Yehuda Ringel ◽  
Nitsan Maharshak

The pathophysiology of irritable bowel syndrome (IBS) is believed to involve alterations in the brain-gut axis; however, the etiological triggers and mechanisms by which these changes lead to symptoms of IBS remain poorly understood. Although IBS is often considered a condition without an identified “organic” etiology, emerging evidence suggests that alterations in the gastrointestinal microbiota and altered immune function may play a role in the pathogenesis of the disorder. These recent data suggest a plausible model in which changes in the intestinal microbiota and activation of the enteric immune system may impinge upon the brain-gut axis, causing the alterations in gastrointestinal function and the clinical symptoms observed in patients with IBS. This review summarizes the current evidence for altered intestinal microbiota and immune function in IBS. It discusses the potential etiological role of these factors, suggests an updated conceptual model for the pathogenesis of the disorder, and identifies areas for future research.


2015 ◽  
Vol 52 (4) ◽  
pp. 331-338 ◽  
Author(s):  
Joaquim Prado MORAES-FILHO ◽  
Eamonn M M QUIGLEY

Irritable bowel syndrome is a common, chronic relapsing gastrointestinal disorder that affects 7%-22% of the population worldwide. According to Rome III Criteria, the disorder is defined by the coexistence of abdominal discomfort or pain associated with an alteration in bowel habits. Its pathophysiology is not completely understood but, in addition to some important abnormalities, the disturbed intestinal microbiota has also been described supported by several strands of evidence. The treatment of irritable bowel syndrome is based upon several therapeutic approaches but few have been successful or without adverse events and more recently the gut microbiota and the use of probiotics have emerged as a factor to be considered. Probiotics are live micro-organisms which when consumed in adequate amounts confer a health benefit to the host, such as Lactic bacteria among others. An important scientific rationale has emerged for the use of probiotics in irritable bowel syndrome, although the data regarding different species are still limited. Not all probiotics are beneficial: it is important to select the specific strain which should be supported by good evidence base. The mechanisms of action of probiotics are described and the main strains are quoted.


2019 ◽  
Vol 2 (13) ◽  
pp. 39-42
Author(s):  
M. S. Turchina ◽  
L. Yu. Korolyova ◽  
M. V. Bukreeva ◽  
E. A. Erofeeva ◽  
D. V. Borzova

Currently, there is an increase in the number of patients with irritable bowel syndrome (IBS). However, to date, there is no single concept of the etiopathogenesis of functional disorders of the digestive tract. Initially, great attention was paid to disorders of motility and impaired regulatory interactions of the brain‑intestine as causes of irritable bowel syndrome, but in recent years the focus has shifted to subclinical inflammation in the colon mucosa and the development of visceral hypersensitivity. The reasons contributing to the formation of immune inflammation in the intestinal wall, include a violation of the composition of the intestinal microbiota, as well as food allergies and food intolerance. This article discusses the qualitative and quantitative changes in the intestinal microbiota in patients with irritable bowel syndrome if they have food allergies, as well as the effect of the composition of the intestinal microbiota on the clinical variant of irritable bowel syndrome. The study included 257 patients with IBS. At the first stage, an assessment was made of the history of food allergies, such as IBS, in accordance with the Bristol scale, as well as a microbiological study of feces. At the second stage, the evaluation of intestinal microbiota correction schemes was carried out in patients who had food allergies. The patients were divided into two equal groups, the first group received intestinal antiseptic in combination with multi‑component probiotic, the second — intestinal antiseptic in combination with Saccharomyces boulardii. When analyzing the obtained results, it was noted that approximately half of patients with IBS in the anamnesis had manifestations of food allergy. In most cases, food allergy was associated with the development of patients with IBS variant with diarrhea and excessive growth of conditionally pathogenic microflora with a decrease in the number of lactic and bifidobacteria. When comparing schemes for the correction of disorders of the intestinal microbiota, the greatest efficacy was observed with the combination of intestinal antiseptic and Saccharomyces boulardii.


Foods ◽  
2018 ◽  
Vol 7 (2) ◽  
pp. 13 ◽  
Author(s):  
Ashton Harper ◽  
Malwina Naghibi ◽  
Davinder Garcha

Irritable bowel syndrome is a highly prevalent gastrointestinal disorder that threatens the quality of life of millions and poses a substantial financial burden on healthcare systems around the world. Intense research into the human microbiome has led to fascinating discoveries which directly and indirectly implicate the diversity and function of this occult organ in irritable bowel syndrome (IBS) pathophysiology. The benefit of manipulating the gastrointestinal microbiota with diet and probiotics to improve symptoms has been demonstrated in a wealth of both animal and human studies. The positive and negative mechanistic roles bacteria play in IBS will be explored and practical probiotic and dietary choices offered.


2021 ◽  
Author(s):  
Fernanda Valdez-Palomares ◽  
Rafael Nambo-Venegas ◽  
Jacqueline Uribe-García ◽  
Alfredo Mendoza-Vargas ◽  
Omar Granados-Portillo ◽  
...  

Irritable Bowel Syndrome (IBS) is a functional gastrointestinal disorder characterized by abdominal pain and altered bowel habit. IBS patients report that FODMAP (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols) diet induce...


Infectio ro ◽  
2017 ◽  
Vol 2 (50) ◽  
Author(s):  
Gabriela-Loredana Popa ◽  
Silvana-Adelina Gheorghe ◽  
Mădălina Preda

2020 ◽  
Vol 0 (3) ◽  
pp. 29-36
Author(s):  
I. A. Derkach ◽  
A. E. Dorofeyev ◽  
M. M. Rudenko ◽  
G. A. Dorofeyeva ◽  
Yu. Z. Dynia

Nutrients ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 649
Author(s):  
Luis Alberto Sánchez-Vargas ◽  
Karina Guadalupe Hernández-Flores ◽  
Francisco Javier Cabrera-Jorge ◽  
José María Remes-Troche ◽  
Job Reyes-Huerta ◽  
...  

Celiac disease (CD) is a chronic immune-mediated enteropathy triggered by exposure to dietary gluten in genetically predisposed individuals. In contrast, irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder affecting the large intestine, without an autoimmune component. Here, we evaluated the prevalence of IgA and IgG antibodies to maize zeins (AZA) in patients with CD and IBS. Using an in-house ELISA assay, the IgA and IgG anti-zein antibodies in the serum of 37 newly diagnosed CD (16 biopsy proved and 21 serological diagnosis) and 375 IBS patients or 302 healthy control (HC) subjects were measured. Elevated levels of IgA AZA were found in CD patients compared with IBS patients (p < 0.01) and HC (p < 0.05). CD patients had the highest prevalence (35.1%), followed by IBS (4.3%) and HCs (2.3%) (p < 0.0001). IgG AZA antibodies were not found in any CD patients, IBS patients, or HC subjects. A significant positive correlation was found between IgA AZA with IgA anti-gliadin (AGA, r = 0.34, p < 0.01) and IgA anti-deaminated gliadin peptides (DGP, r = 0.42, p < 0.001) in the celiac disease group. Taken together, our results show for the first time a higher prevalence of AZA IgA antibodies in newly diagnosed CD patients than in IBS patients, confirming a biased immune response to other gliadin-related prolamins such as maize zeins in genetically susceptible individuals.


Sign in / Sign up

Export Citation Format

Share Document